Gilead Sciences (GILD) Current Assets (2009 - 2026)

Gilead Sciences (GILD) has reported Current Assets for 18 consecutive years, with $13.9 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Assets fell 5.25% year-over-year to $13.9 billion; the trailing twelve-month figure through Jun 2026 stood at $13.9 billion (down 5.25% YoY), and the FY2025 full-year result was $18.3 billion, down 4.33% from the prior year.
• Current Assets retreated to $13.9 billion in Q2 2026 per GILD's latest filing, from $18.6 billion in the prior quarter.
• Across five years, Current Assets topped out at $19.2 billion in Q4 2024 and bottomed at $12.3 billion in Q2 2024.
• Historically, Current Assets has averaged $15.2 billion across 5 years, with a median of $14.6 billion in 2022.
• The sharpest annual moves came in 2024 and 2025: Current Assets retreated 13.79% in 2024, then advanced 20.94% in 2025.
• Over 5 years, Current Assets stood at $14.4 billion in 2022, then advanced by 11.37% to $16.1 billion in 2023, then climbed by 19.2% to $19.2 billion in 2024, then retreated by 4.33% to $18.3 billion in 2025, then fell by 23.97% to $13.9 billion in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $13.9 billion, $18.6 billion, and $18.3 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.